Melatonin and depression : a translational perspective from animal models to clinical studies
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/240285 |
Resumo: | Daily rhythm of melatonin synchronizes the body to the light/dark environmental cycle. Several hypotheses have been raised to understand the intersections between melatonin and depression, in which changes in rest-activity and sleep patterns are prominent. This review describes key experimental and clinical evidence that link melatonin with the etiopathology and symptomatology of depressive states, its role in the follow up of therapeutic response to antidepressants, as well as the clinical evidence of melatonin as MDD treatment. Melatonin, as an internal temporal cue contributing to circadian organization and best studied in the context of circadian misalignment, is also implicated in neuroplasticity. The monoaminergic systems that underly MDD and melatonin production overlap. In addition, the urinary metabolite 6-sulfatoxymelatonin (aMT6) has been proposed as biomarker for antidepressant responders, by revealing whether the blockage of noradrenaline uptake has taken place within 24 h from the first antidepressant dose. Even though animal models show benefits from melatonin supplementation on depressive-like behavior, clinical evidence is inconsistent vis-à-vis prophylactic or therapeutic benefits of melatonin or melatonin agonists in depression. We argue that the study of melatonin in MDD or other psychiatric disorders must take into account the specificities of melatonin as an integrating molecule, inextricably linked to entrainment, metabolism, immunity, neurotransmission, and cell homeostasis. |
id |
UFRGS-2_f5b6adeda2f195fb860f29837fcc5ed3 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/240285 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Tonon, André ComiranPilz, Luísa KlausMarkus, Regina PekelmannHidalgo, Maria Paz LoayzaElisabetsky, Elaine2022-06-15T04:42:31Z20211664-0640http://hdl.handle.net/10183/240285001139782Daily rhythm of melatonin synchronizes the body to the light/dark environmental cycle. Several hypotheses have been raised to understand the intersections between melatonin and depression, in which changes in rest-activity and sleep patterns are prominent. This review describes key experimental and clinical evidence that link melatonin with the etiopathology and symptomatology of depressive states, its role in the follow up of therapeutic response to antidepressants, as well as the clinical evidence of melatonin as MDD treatment. Melatonin, as an internal temporal cue contributing to circadian organization and best studied in the context of circadian misalignment, is also implicated in neuroplasticity. The monoaminergic systems that underly MDD and melatonin production overlap. In addition, the urinary metabolite 6-sulfatoxymelatonin (aMT6) has been proposed as biomarker for antidepressant responders, by revealing whether the blockage of noradrenaline uptake has taken place within 24 h from the first antidepressant dose. Even though animal models show benefits from melatonin supplementation on depressive-like behavior, clinical evidence is inconsistent vis-à-vis prophylactic or therapeutic benefits of melatonin or melatonin agonists in depression. We argue that the study of melatonin in MDD or other psychiatric disorders must take into account the specificities of melatonin as an integrating molecule, inextricably linked to entrainment, metabolism, immunity, neurotransmission, and cell homeostasis.application/pdfengFrontiers in psychiatry. Lausanne. Vol. 12 (2021), 638981, 13 p.BiomarcadoresTranstornos do humorRitmo circadianoCronobiologiaDepressãoMelatoninaModelos animaisEstudo clínicoPsychiatryMood disorderNeuropsychaitric disordersBehaviorBiological rhythmsChronobiology6-sulfatoxymelatonin (aMT6s)BiomarkerMelatonin and depression : a translational perspective from animal models to clinical studiesEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001139782.pdf.txt001139782.pdf.txtExtracted Texttext/plain78938http://www.lume.ufrgs.br/bitstream/10183/240285/2/001139782.pdf.txt77276d8368266b3ba2dac92af98723b3MD52ORIGINAL001139782.pdfTexto completo (inglês)application/pdf873281http://www.lume.ufrgs.br/bitstream/10183/240285/1/001139782.pdfb286a61ec21a35404800d19a14df33c2MD5110183/2402852022-06-16 04:41:31.055454oai:www.lume.ufrgs.br:10183/240285Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2022-06-16T07:41:31Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Melatonin and depression : a translational perspective from animal models to clinical studies |
title |
Melatonin and depression : a translational perspective from animal models to clinical studies |
spellingShingle |
Melatonin and depression : a translational perspective from animal models to clinical studies Tonon, André Comiran Biomarcadores Transtornos do humor Ritmo circadiano Cronobiologia Depressão Melatonina Modelos animais Estudo clínico Psychiatry Mood disorder Neuropsychaitric disorders Behavior Biological rhythms Chronobiology 6-sulfatoxymelatonin (aMT6s) Biomarker |
title_short |
Melatonin and depression : a translational perspective from animal models to clinical studies |
title_full |
Melatonin and depression : a translational perspective from animal models to clinical studies |
title_fullStr |
Melatonin and depression : a translational perspective from animal models to clinical studies |
title_full_unstemmed |
Melatonin and depression : a translational perspective from animal models to clinical studies |
title_sort |
Melatonin and depression : a translational perspective from animal models to clinical studies |
author |
Tonon, André Comiran |
author_facet |
Tonon, André Comiran Pilz, Luísa Klaus Markus, Regina Pekelmann Hidalgo, Maria Paz Loayza Elisabetsky, Elaine |
author_role |
author |
author2 |
Pilz, Luísa Klaus Markus, Regina Pekelmann Hidalgo, Maria Paz Loayza Elisabetsky, Elaine |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Tonon, André Comiran Pilz, Luísa Klaus Markus, Regina Pekelmann Hidalgo, Maria Paz Loayza Elisabetsky, Elaine |
dc.subject.por.fl_str_mv |
Biomarcadores Transtornos do humor Ritmo circadiano Cronobiologia Depressão Melatonina Modelos animais Estudo clínico |
topic |
Biomarcadores Transtornos do humor Ritmo circadiano Cronobiologia Depressão Melatonina Modelos animais Estudo clínico Psychiatry Mood disorder Neuropsychaitric disorders Behavior Biological rhythms Chronobiology 6-sulfatoxymelatonin (aMT6s) Biomarker |
dc.subject.eng.fl_str_mv |
Psychiatry Mood disorder Neuropsychaitric disorders Behavior Biological rhythms Chronobiology 6-sulfatoxymelatonin (aMT6s) Biomarker |
description |
Daily rhythm of melatonin synchronizes the body to the light/dark environmental cycle. Several hypotheses have been raised to understand the intersections between melatonin and depression, in which changes in rest-activity and sleep patterns are prominent. This review describes key experimental and clinical evidence that link melatonin with the etiopathology and symptomatology of depressive states, its role in the follow up of therapeutic response to antidepressants, as well as the clinical evidence of melatonin as MDD treatment. Melatonin, as an internal temporal cue contributing to circadian organization and best studied in the context of circadian misalignment, is also implicated in neuroplasticity. The monoaminergic systems that underly MDD and melatonin production overlap. In addition, the urinary metabolite 6-sulfatoxymelatonin (aMT6) has been proposed as biomarker for antidepressant responders, by revealing whether the blockage of noradrenaline uptake has taken place within 24 h from the first antidepressant dose. Even though animal models show benefits from melatonin supplementation on depressive-like behavior, clinical evidence is inconsistent vis-à-vis prophylactic or therapeutic benefits of melatonin or melatonin agonists in depression. We argue that the study of melatonin in MDD or other psychiatric disorders must take into account the specificities of melatonin as an integrating molecule, inextricably linked to entrainment, metabolism, immunity, neurotransmission, and cell homeostasis. |
publishDate |
2021 |
dc.date.issued.fl_str_mv |
2021 |
dc.date.accessioned.fl_str_mv |
2022-06-15T04:42:31Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/240285 |
dc.identifier.issn.pt_BR.fl_str_mv |
1664-0640 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001139782 |
identifier_str_mv |
1664-0640 001139782 |
url |
http://hdl.handle.net/10183/240285 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Frontiers in psychiatry. Lausanne. Vol. 12 (2021), 638981, 13 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/240285/2/001139782.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/240285/1/001139782.pdf |
bitstream.checksum.fl_str_mv |
77276d8368266b3ba2dac92af98723b3 b286a61ec21a35404800d19a14df33c2 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1815447795185745920 |